AbbVie reported strong Q1 2026 results with immunology revenue rising 12.4% year-over-year, led by Skyrizi and Rinvoq growth. Despite a 46% net income drop due to a large R&D charge and declines in older drugs like Humira, the company’s pipeline and new drug momentum support long-term growth. Analysts see about 14% upside in the next year, but a $300 share price by 2030 is feasible if key drugs maintain growth and R&D charges normalize. The stock currently trades at a low forward P/E of 17x, making the multi-year target realistic if risks like legacy drug erosion are managed.
AbbVie continues strong growth in immunology, with Skyrizi and Rinvoq products compensating for declines in Humira sales. The expansion of Skyrizi's use in Crohn's Disease and Rinvoq's approvals for alopecia areata and vitiligo are expected to furthe...
AbbVie reported Q1 2026 revenue of $15 billion, beating expectations, and raised its full-year adjusted EPS guidance to $14.08-$14.28. The company maintains a nearly 3% dividend yield, supported by a healthy free cash flow payout ratio of 65.4% and s...
The Schwab U.S. Dividend Equity ETF (SCHD) has a top 10 holdings concentration of 41%, higher than typical dividend ETFs, focusing heavily on energy, healthcare, and consumer staples. While SCHD offers low fees and a solid dividend yield near 3.9%, i...
